KRAS G12C突变在消化系统恶性肿瘤中的分子特点

肝癌电子杂志 ›› 2024, Vol. 11 ›› Issue (1): 4-8.

KRAS G12C突变在消化系统恶性肿瘤中的分子特点

赵挺祺¹, 董林², 应建明², 李卫华^2,*

1.巴彦淖尔市医院病理科,内蒙古巴彦淖尔市 015000;
2.国家癌症中心/国家肿瘤临床研究中心/中国医学科学院北京协和医学院肿瘤医院病理科,北京 100021

收稿日期:2022-12-06 出版日期:2024-03-31 发布日期:2024-05-08
通讯作者: ^*李卫华,E-mail: liweihua@cicams.ac.cn;应建明,E-mail: jmying@cicams.ac.cn

Molecular characterization of KRAS G12C mutation in the tumors of digestive system

Zhao Tingqi¹, Dong Lin², Ying Jianming^2,*, Li Weihua^2,*

1. Department of Pathology, Bayan Nur Hospital, Bayan Nur 015000, China;
2. Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Received:2022-12-06 Online:2024-03-31 Published:2024-05-08
Contact: ^*Ying Jianming,E-mail: liweihua@cicams.ac.cn; Li Weihua, E-mail: jmying@cicams.ac.cn

摘要/Abstract

摘要： 目的: 探究KRAS G12C突变在不同消化系统恶性肿瘤中的发生率及分子病理特点。
方法: 收集2017—2022 年在中国医学科学院肿瘤医院诊断为消化系统恶性肿瘤且有肿瘤组织样本的1 100例患者资料。使用二代测序的方法对1 100例消化系统恶性肿瘤组织样本（包括结肠腺癌、直肠腺癌、回盲肠腺癌、十二指肠腺癌、胃腺癌、胆管腺癌和胰腺导管腺癌）的微卫星状态和肿瘤突变负荷（TMB）,以及KRAS、NRAS、BRAF、PIK3CA突变进行检测。
结果: 微卫星高度不稳定（MSI-H）在不同消化系统肿瘤中存在差异,其中在十二指肠腺癌发生率最高（19%）,其次为回盲肠腺癌（18%）和结肠腺癌（10.2%）,但在100例胰腺导管腺癌中未检出MSI-H的肿瘤。不同消化系统恶性肿瘤的TMB值亦有差异,高TMB（≥10 mut/Mb）在回盲肠腺癌中最常见（24%）,其次为十二指肠腺癌（22%）和胃腺癌（18.9%）。KRAS在总人群中的突变率为41.09%,其中在胰腺导管腺癌中突变率最高（85.0%）,其次为十二指肠腺癌（56%）和回盲肠腺癌（53%）,在胃腺癌中最低（7.3%）。KRAS G12C在总人群中的突变率为2.82%（31/1 100）,在所有KRAS突变的消化系统肿瘤中仅占6.9%（31/452）,常见于回盲肠腺癌（2/9）,其次为十二指肠腺癌（13%）和结肠腺癌（8.8%）。KRAS G12C突变和其他KRAS突变亚型患者的性别、年龄、MSI和TMB状态相近。
结论: 虽然近一半的消化系统恶性肿瘤患者携带有KRAS突变,但KRAS G12C突变发生率相对较低,只占KRAS突变人群的6.9%。KRAS G12C突变最常见于回盲肠腺癌、十二指肠腺癌和结肠腺癌,且与其他类型的KRAS突变相比未见明显的临床和分子病理特征差异。

关键词: 消化系统肿瘤, 二代测序, KRAS G12C突变

Abstract: Objective: To identified the molecular characteristics of KRAS G12C mutation in the tumors of digestive system.
Methods: Data of 1 100 patients diagnosed as digestive malignant tumor in Cancer Hospital of Chinese Academy of Medical Sciences from 2017 to 2022 were collected. The microsatellite status, tumor mutation burden (TMB) and KRAS, NRAS, BRAF and PIK3CA mutations were detected by next-generation sequencing in 1 100 patients with tumors of digestive system, including colorectal adenocarcinoma, duodenal adenocarcinoma, cholangiocarcinoma, gastric adenocarcinoma, ileocecal adenocarcinoma and pancreatic ductal adenocarcinoma.
Results: Microsatellite instability-high (MSI-H) tumors were most common in duodenal adenocarcinoma (19%), followed by ileocecal adenocarcinoma (18%) and colorectal adenocarcinoma (10.2%). However, no MSI-H tumors were detected in the 100 cases of pancreatic ductal adenocarcinoma. TMB values also varied among different tumors of digestive system. High-TMB (≥10 mut/Mb) tumors were most common in ileocecal adenocarcinoma (24%), followed by duodenal adenocarcinoma (22%) and gastric adenocarcinoma (18.9%). KRAS mutations were detected in 452 of 1 100 (41.09%) cases, among which the most common tumor was pancreatic ductal adenocarcinoma (85.0%), followed by duodenal adenocarcinoma (56%) and ileocecal adenocarcinoma (53%). However, KRAS mutations were identified in 7.3% of gastric adenocarcinoma. KRAS G12C mutation was detected in 2.82% of all the 1 100 tumors, and only 6.9% (31/452) of all digestive tumors with KRAS mutations among which the most common tumor was ileocecal adenocarcinoma (2/9), followed by duodenal adenocarcinoma (13%) and colorectal adenocarcinoma (8.8%). However, no significant differences in gender, age, MSI and TMB status were observed between patients with KRAS G12C mutation and other KRAS mutation subtypes.
Conclusions: Although nearly half of patients with digestive malignancies carry KRAS mutations, but only 6.9% of KRAS-mutant cases harbored KRAS G12C mutation subtype. KRAS G12C mutation was most common in ileocecal cancer, duodenal cancer and colorectal cancer. And no obvious difference in clinical and molecular pathological features compared with other types of KRAS mutations

Key words: Tumors of digestive system, Next-generation sequencing, KRAS G12C mutation

赵挺祺, 董林, 应建明, 李卫华. KRAS G12C突变在消化系统恶性肿瘤中的分子特点[J]. 肝癌电子杂志, 2024, 11(1): 4-8.

Zhao Tingqi, Dong Lin, Ying Jianming, Li Weihua. Molecular characterization of KRAS G12C mutation in the tumors of digestive system[J]. Electronic Journal of Liver Tumor, 2024, 11(1): 4-8.

参考文献

[1] CANCER GENOME ATLAS NETWORK. Comprehensive molecular characterization of human colon and rectal cancer[J]. Nature, 2012, 487(7407): 330-337.
[2] SUNG H, FERLAY J, SIEGEL R L, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[3] 王欣宇,张同梅,李宝兰. 晚期非小细胞肺癌KRAS突变治疗的研究进展[J]. 中华肿瘤防治杂志, 2020,27(21):1763-1769.
[4] LUDOVINI V, RICCIUTI B, TOFANETTI F R, et al.KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer[J]. Mol Clin Oncol, 2018, 9(6): 689-696.
[5] NADAL E, BEER D G, RAMNATH N.KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma[J]. J Thorac Oncol, 2015. 10(2): e9-e10.
[6] SVATON M, FIALA O, PESEK M, et al.The prognostic role of KRAS mutation in patients with advanced NSCLC treated with second- or third-line chemotherapy[J]. Anticancer Res, 2016, 36(3): 1077-1082.
[7] 杨学超,田延龙,高晓,等. 胃癌临床病理特征与KRAS基因突变的相关性研究[J]. 中国肿瘤临床与康复,2020,27(5):582-585.
[8] 吴永芳,许春伟,宋业颖,等. 结直肠癌患者肿瘤组织中KRAS、NRAS和BRAF基因突变的分子病理检测分析[J]. 临床与病理杂志,2015,35(7):1385-1389.
[9] 凌云,应建明,邱田,等. 结直肠癌患者KRAS、BRAF及PIK3CA基因突变检测分析[J]. 中华病理学杂志,2012,41(9):590-594.
[10] HUTAREW G.PD-L1 testing, fit for routine evaluation? From a pathologist's point of view[J]. Memo, 2016, 9(4): 201-206.
[11] POSTOW M A, CALLAHAN M K, WOLCHOK J D.Immune checkpoint blockade in cancer therapy[J]. J Clin Oncol, 2015, 33(17): 1974-1982.
[12] SHEKARIAN T, VALSESIA-WITTMANN S, BRODY J, et al.Pattern recognition receptors: immune targets to enhance cancer immunotherapy[J]. Ann Oncol, 2017, 28(8): 1756-1766.
[13] SOMASUNDARAM A, BURNS T F.Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives[J]. Lung Cancer (Auckl), 2017, 8: 1-11.
[14] VILLARUZ L C, ANCEVSKI-HUNTER K, KURLAND B F, et al.Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice[J]. Histopathology, 2019. 74(2): 269-275.
[15] MCGRANAHAN N, FURNESS A J, ROSENTHAL R, et al.Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade[J]. Science, 2016, 351(6280): 1463-1469.
[16] LUCHINI C, BIBEAU F, LIGTENBERG M, et al.ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach[J]. Ann Oncol, 2019, 30(8): 1232-1243.
[17] TSUCHIDA N, MURUGAN A K, GRIECO M.Kirsten Ras* oncogene: significance of its discovery in human cancer research[J]. Oncotarget, 2016, 7(29): 46717-46733.
[18] PRIEUR A, CAPPELLINI M, HABIF G, et al.Targeting the wnt pathway and cancer stem cells with anti-progastrin humanized antibodies as a potential treatment for K-RAS-mutated colorectal cancer[J]. Clin Cancer Res, 2017, 23(17): 5267-5280.
[19] KARMAKAR S, KAUSHIK G, NIMMAKAYALA R, et al.MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention[J]. Semin Cancer Biol, 2019, 54: 63-71.
[20] CAVALLONI G, PERALDO-NEIA C, SASSI F, et al.Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation[J]. BMC Cancer, 2016, 16: 90.
[21] CHAN E.Angiogenesis in colorectal cancer: antibodies[J]. Cancer J, 2016, 22(3): 179-181.
[22] LOONG HH, DU N, CHENG C, et al.KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples[J]. Transl Lung Cancer Res, 2020, 9(5): 1759-1769.
[23] TAM CS, TROTMAN J, OPAT S, et al.Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL[J]. Blood, 2019, 134(11): 851-859.
[24] HONG D S, FAKIH M G, STRICKLER J H, et al.KRASG12C inhibition with sotorasib in advanced solid tumors[J]. N Engl J Med, 2020, 383(13): 1207-1217.
[25] HALLIN J, ENGSTROM LD, HARGIS L, et al.The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients[J]. Cancer Discov, 2020, 10(1): 54-71.
[26] OU S I, JÄNNE P A, LEAL T A, et al. First-in-human phase Ⅰ/ⅠB dose-finding study of adagrasib (MRTX849) in patients with advanced KRASG12C solid tumors (KRYSTAL-1)[J]. J Clin Oncol, 2022, 40(23): 2530-2538.
[27] YARI A, AFZALI A, AALIPOUR M, et al.KRAS and BRAF mutations in Iranian colorectal cancer patients: a systematic review and Meta-analysis[J]. Caspian J Intern Med, 2020, 11(4): 355-369.
[28] 梁跃,李光学, 马庆庆. 结直肠癌KRAS、NRAS、PIK3CA、BRAF基因联合突变分析及临床意义[J]. 中国社区医师,2018,34(14): 107-109.
[29] 刘晓晴,范杰,黄淑梅. 靶向肿瘤KRAS突变的T细胞过继免疫治疗[J]. 循证医学,2017,17(1):37-41.